tetano
Editor, Senior Moderator
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 29;43(0):E026. doi: 10.3760/cma.j.cn112147-20200224-00159. [Epub ahead of print] [The keypoints in treatment of the critical coronavirus disease 2019 patient].
[Article in Chinese; Abstract available in Chinese from the publisher]
Li XY[SUP]1[/SUP], Du B[SUP]2[/SUP], Wang YS[SUP]1[/SUP], Kang HYJ[SUP]1[/SUP], Wang F[SUP]1[/SUP], Sun B[SUP]1[/SUP], Qiu HB[SUP]3[/SUP], Tong ZH[SUP]1[/SUP].
Author information
Abstract
in English, Chinese
The treatment of critically ill patients with coronavirus disease 2019(COVID-19) faces compelling challenges. In this issue, we'd like to share our first-line treatment experience in treating COVID-19. Hemodynamics need be closely monitored and different types of shock should be distinguished. Vasoconstrictor drugs should be used rationally and alerting of complications is of the same importance. The risk of venous thromboembolism (VTE) needs to be assessed, and effective prevention should be carried out for high-risk patients. It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure. However, comprehensive analysis of disease state should be taken into the interpretation of abnormally elevated D-Dimer. Nutritional support is the basis of treatment. It's important to establish individual therapy regimens and to evaluate, monitor and adjust dynamically. Under the current epidemic situation, convalescent plasma can only be used empirically, indications need to be strictly screened, the blood transfusion process should be closely monitored and the curative effect should be dynamically evaluated.
KEYWORDS:
Convalescent plasma; Coronavirus disease 2019, COVID-19; Nutritional support; Vasoconstrictor drugs; Venous thromboembolism
PMID: 32111113 DOI: 10.3760/cma.j.cn112147-20200224-00159
[Article in Chinese; Abstract available in Chinese from the publisher]
Li XY[SUP]1[/SUP], Du B[SUP]2[/SUP], Wang YS[SUP]1[/SUP], Kang HYJ[SUP]1[/SUP], Wang F[SUP]1[/SUP], Sun B[SUP]1[/SUP], Qiu HB[SUP]3[/SUP], Tong ZH[SUP]1[/SUP].
Author information
Abstract
in English, Chinese
The treatment of critically ill patients with coronavirus disease 2019(COVID-19) faces compelling challenges. In this issue, we'd like to share our first-line treatment experience in treating COVID-19. Hemodynamics need be closely monitored and different types of shock should be distinguished. Vasoconstrictor drugs should be used rationally and alerting of complications is of the same importance. The risk of venous thromboembolism (VTE) needs to be assessed, and effective prevention should be carried out for high-risk patients. It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure. However, comprehensive analysis of disease state should be taken into the interpretation of abnormally elevated D-Dimer. Nutritional support is the basis of treatment. It's important to establish individual therapy regimens and to evaluate, monitor and adjust dynamically. Under the current epidemic situation, convalescent plasma can only be used empirically, indications need to be strictly screened, the blood transfusion process should be closely monitored and the curative effect should be dynamically evaluated.
KEYWORDS:
Convalescent plasma; Coronavirus disease 2019, COVID-19; Nutritional support; Vasoconstrictor drugs; Venous thromboembolism
PMID: 32111113 DOI: 10.3760/cma.j.cn112147-20200224-00159